Isoniazid Monotherapy for TB Prevention

Isoniazid monotherapy is a treatment used to prevent active tuberculosis in individuals who have been exposed to M. tuberculosis. However, it is important to note that isoniazid-induced hepatitis can occur in approximately 1% of patients, with a higher risk in those over the age of 35. The risk of hepatitis is less than 0.3% in patients under 20 years old, but increases to 2-3% in individuals over 50 years old.

Aside from hepatitis, other side effects of isoniazid therapy include peripheral neuritis, which can be prevented by taking pyridoxine prophylactically. Additionally, a systemic lupus erythematosus (SLE)-like syndrome may also occur. It is important for healthcare providers to monitor patients closely for any adverse reactions while on isoniazid therapy.

Pyrimethamine and sulphadiazine are the recommended treatment for toxoplasmosis in immunocompromised patients, such as this man with a history of HIV who is non-compliant with treatment. His positive toxoplasmosis serology and the presence of multiple ring-enhancing lesions on CT support this diagnosis. Co-trimoxazole and prednisolone are used for Pneumocystis jirovecii pneumonia, but this is not suspected in this case as there are no chest symptoms. Fluconazole is effective against fungal infections like candidiasis, while amphotericin B is used for cryptococcal infection, which is not the likely diagnosis in this patient as his cryptococcus serology is negative and there are no signs of cerebral oedema or meningeal enhancement on CT.

Toxoplasmosis: A Protozoan Infection

Toxoplasmosis is caused by the protozoan Toxoplasma gondii, which enters the body through the gastrointestinal tract, lungs, or broken skin. The disease is commonly found in cats, but other animals like rats can also carry it. The infection is usually asymptomatic, but symptomatic patients may experience fever, malaise, and lymphadenopathy. In rare cases, toxoplasmosis can cause meningoencephalitis and myocarditis. Serology is the preferred diagnostic test, and treatment is only necessary for severe infections or immunosuppressed patients.

In immunosuppressed patients, toxoplasmosis can cause cerebral toxoplasmosis, which accounts for half of cerebral lesions in HIV patients. Symptoms include headache, confusion, and drowsiness, and CT scans may show single or multiple ring-enhancing lesions with mass effect. Treatment involves pyrimethamine and sulphadiazine for at least six weeks. Immunocompromised patients may also develop chorioretinitis due to toxoplasmosis.

Congenital toxoplasmosis occurs when the infection is transmitted from mother to fetus through the placenta. It can cause neurological damage, cerebral calcification, hydrocephalus, chorioretinitis, ophthalmic damage, retinopathy, and cataracts in the unborn child.

Treatment Options for Shigella Infection

Shigella infection is a common cause of diarrhoea, particularly in developing countries. The following treatment options are available for patients with symptomatic Shigella infection:

Oral azithromycin is the preferred first-line option for the treatment of Shigella infection. Quinolones were previously used, but their use is now discouraged due to the risk of seizures and tendon rupture.

Oral metronidazole is the intervention of choice for giardiasis, which presents with symptoms similar to irritable bowel syndrome. However, Shigella infection is not usually treated with metronidazole.

Oral ciprofloxacin is now reserved for serious or life-threatening illness when other options for treatment are unavailable due to significant adverse effects associated with their use.

Single-dose intravenous (IV) ceftriaxone is the preferred option for patients who are severely unwell because of Shigella infection. However, oral azithromycin is considered adequate for most cases.

Given the severity of symptoms and the patient’s activity holiday, antibiotic intervention is warranted to relieve his symptoms.

Antifungal Therapy in Haematology Patients

In haematology patients who are at risk of invasive fungal infections, it is no longer recommended to start empirical therapy with systemic antifungals. The latest guidelines from the British Committee for Standards in Haematology suggest that before initiating antifungal therapy, serological and/or imaging/biopsy should be performed to confirm the presence of a fungal infection. Among these modalities, imaging is the preferred choice as it is less invasive and more readily available.

In summary, haematology patients who are susceptible to fungal infections should not be given antifungal therapy without first confirming the presence of a fungal infection through serological and/or imaging/biopsy. Imaging is the preferred diagnostic tool due to its non-invasive nature and accessibility.

Treatment for Influenza B with Pneumonitis

Influenza B with pneumonitis requires treatment with oseltamivir 75 mg twice daily for 5 days. However, if the patient had no complications, treatment may not be necessary unless the physician deems it necessary. Oseltamivir is the first line therapy for Influenza B, while zanimivir is a second line therapy for Influenza B and first line for Influenza A. These guidelines are based on the PHE guidance on the use of antiviral agents for the treatment and prophylaxis of seasonal influenza. It is important to follow these guidelines to ensure proper treatment and management of influenza infections.

Prompt and definitive action is crucial in the treatment of necrotising fasciitis, as any delay can heighten the risk of fatality. Although IV aciclovir is necessary in addressing acute varicella infection, the primary focus should be on eliminating the source of the bacterial infection. While chickenpox may have contributed to the patient’s condition, it is not the root cause of their deteriorating health or necrotic skin. While MRI can provide confirmation of the extent of necrotising fasciitis, it may impede surgical debridement. Given the patient’s critical condition, immediate and decisive management is imperative.

Chickenpox is a viral infection caused by the varicella zoster virus. It is highly contagious and can be spread through respiratory droplets. The virus can also reactivate later in life and cause shingles. Chickenpox is most infectious from four days before the rash appears until five days after. The incubation period is typically 10-21 days. Symptoms include fever and an itchy rash that starts on the head and trunk before spreading. The rash goes through stages of macular, papular, and vesicular. Management is supportive, with measures such as keeping cool and using calamine lotion. Immunocompromised patients and newborns with peripartum exposure should receive varicella zoster immunoglobulin. Complications can include secondary bacterial infection of the lesions, pneumonia, encephalitis, and rare complications such as disseminated haemorrhagic chickenpox.

One common complication of chickenpox is secondary bacterial infection of the lesions, which can be increased by the use of NSAIDs. This can manifest as a single infected lesion or small area of cellulitis. In rare cases, invasive group A streptococcal soft tissue infections may occur, resulting in necrotizing fasciitis. Other rare complications of chickenpox include pneumonia, encephalitis (which may involve the cerebellum), disseminated haemorrhagic chickenpox, and very rarely, arthritis, nephritis, and pancreatitis. It is important to note that school exclusion may be necessary, as chickenpox is highly infectious and can be caught from someone with shingles. It is advised to avoid contact with others until all lesions have crusted over.

Management of Septic Shock

Septic shock is a medical emergency that requires early and aggressive therapy with broad-spectrum empirical antibiotics. While a pulmonary embolus may account for some of the symptoms, a gradual deterioration with a systemic inflammatory response (SIRS) response is more indicative of sepsis. The Sequential Organ Failure Assessment (SOFA) score in the ICU is a useful tool in screening for patients likely to have sepsis.

Fluid resuscitation should be the first priority, although vasopressors may be necessary. If a pulmonary embolus is suspected, an x-ray should be done first, followed by an echocardiogram if necessary. Blood cultures, antibiotics, fluid, oxygen, lactate, and accurate urine output measurement are higher priorities. If the patient is still intubated or has a tracheostomy, a non-directed bronchial lavage may help diagnose the offending pathogen, but the patient may need to be stabilized first.

Before initiating inotropes, fluid resuscitation should occur. Lung ultrasound and focused intensive care ultrasound are ideal in this scenario to determine the cause of shock. Lung ultrasound can demonstrate collapse and consolidation of the right base and guide fluid resuscitation before inotropes are initiated. A transthoracic echocardiogram may help exclude a massive pulmonary embolus, but this diagnosis is less likely.

In summary, septic shock requires prompt and aggressive management with broad-spectrum antibiotics and fluid resuscitation. The SOFA score is a useful tool in screening for sepsis, and lung ultrasound can help guide fluid resuscitation before inotropes are initiated.

Nocardia is a type of Gram-positive rod-shaped bacteria that can cause pneumonia and brain abscesses, particularly in individuals with weakened immune systems. This bacteria is similar to Actinomyces in that it forms fungus-like branched networks of hyphae-like filaments. However, Nocardia is not anaerobic like Actinomyces. The disease caused by Nocardia is often chronic and progressive, and can be difficult to treat. It is important for individuals with weakened immune systems to take precautions to avoid exposure to this bacteria.

Treatment Options for a HIV-Positive Patient with Respiratory Infection

When treating a HIV-positive patient with respiratory infection, it is important to consider the patient’s history and symptoms to determine the appropriate course of treatment. In this case, the patient’s symptoms suggest a community-acquired pneumonia, which can be treated with amoxicillin and clarithromycin according to NICE guidelines.

If the patient is diagnosed with Pneumocystis jirovecii pneumonia (PCP), clindamycin and primaquine would be the second-line treatment if the patient cannot tolerate co-trimoxazole. IV co-trimoxazole would be the first-line treatment for PCP, but it is not the most likely diagnosis in this case.

Liposomal amphotericin is used to treat severe fungal infections or leishmaniasis, which is not the most likely diagnosis for this patient. Metronidazole would be used to treat an intra-abdominal cause of infection rather than a respiratory infection.

It is important to consider the patient’s CD4 count and susceptibility to opportunistic infections when determining the appropriate treatment for a HIV-positive patient with respiratory infection. Voriconazole can be used for invasive aspergillosis, which is a potential risk for patients with low CD4 counts. However, in this case, the clinical picture is more consistent with an atypical chest infection rather than PCP or invasive aspergillosis.

Hepatitis B Markers

Hepatitis B is a viral infection that affects the liver. There are several markers that can be used to diagnose and monitor the progression of the disease. One of these markers is the hepatitis B core antigen (HBcAg), which is found inside infected cells. Another marker is the anti-HBc antibody, which is present throughout the infection. In acute infections, anti-HBc of the IgM class is present and persists between the disappearance of HBsAg and the appearance of anti-HBs. In patients recovering from acute infection, anti-HBc of the IgG class is present along with anti-HBs, while in those with chronic infection, it is present with HBsAg.

Isolated anti-HBc can signify three possibilities: the patient is in the period of acute hepatitis B, anti-HBs has fallen to undetectable levels following recovery from acute hepatitis B, or chronic HBV infection where the HBsAg titre has fallen to undetectable levels. Another marker is the HBe antigen, which indicates replication and infectivity. HBe Ag to anti-HBe antibody seroconversion usually occurs early in acute infection, but it can be delayed for many years in patients with chronic hepatitis B infection. Finally, the ALT may be normal in an inactive carrier state. these markers is crucial for the diagnosis and management of hepatitis B.